Safety Analyses of Clinical Data for Bifeprunox in Patients with
Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar
to Placebo
...fort.
"These analyses of Phase 2 and Phase 3 studies point out the
favorable weight and metabolic profile of patients who received
bifeprunox," says
earl Sands, M.D., Vice President, Research and
Development at Solvay Pharmaceuticals, Inc. "Patients with
schizophrenia have a high risk of developing meta...
New Long-Term Data Analyses for Bifeprunox Show Favorable Effects
Versus Placebo in Stabilized Patients with Schizophrenia
... asthenia.
"We are encouraged by these additional analyses of clinical
data, which underscore bifeprunox's favorable weight and lipid
profile," says
earl Sands, M.D., Vice President, Research and
Development at Solvay Pharmaceuticals, Inc. "Bifeprunox, if
approved, may be an important treatment option i...